Back to top
Top
U.S. flag

An official website of the United States government

DERep Home Page

["Type": "Adverse Reaction To Thrombolytics"]

Performance/Reporting Period
2023
Value Set Description from VSAC
Clinical Focus: The purpose of this value set is to represent concepts for adverse reactions to thrombolytic medications used for treatment of ST-segment elevation myocardial infaction (STEMI).
Data Element Scope: This value set may use a model element related to Disorder.
Inclusion Criteria: Includes SNOMED-CT codes that represent adverse reactions to thrombolytic medications for STEMI treatment.
Exclusion Criteria: No exclusions.

Constrained to codes in the Type: Adverse Reaction To Thrombolytics value set (2.16.840.1.113762.1.4.1170.6)

QDM Datatype and Definition

type

The characterization of the reaction (e.g., hypersensitivity, rash, gastroenteric symptoms, etc.).
eCQMs using this data element:
CMS996v3 - Appropriate Treatment for ST-Segment Elevation Myocardial Infarction (STEMI) Patients in the Emergency Department (ED)
Last Updated: Jan 15, 2024

We want your feedback

For technical questions about eCQMs, please log in to the ONC Project Tracking System, specifically the eCQM Issue Tracker.

eCQI Resource Center Feedback pertains to:
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.